C. Klein

发表

Risk Factors for High Mortality on the Liver Transplant Waiting List in Times of Organ Shortage: A Single-Center Analysis

A. Paul, D. Hoyer, F. Saner, 2019, Annals of transplantation.

Liver transplantation with donors over the expected lifespan in the model for end‐staged liver disease era: is Mother Nature punishing us?

V. Cicinnati, S. Beckebaum, E. Molmenti, 2011, Liver international : official journal of the International Association for the Study of the Liver.

Impact of combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy on renal function, cardiovascular risk factors, and graft function in liver transplant patients: preliminary results of an open prospective study.

G. Gerken, V. Cicinnati, S. Beckebaum, 2004, Transplantation proceedings.

Pharmacokinetics of Mycophenolic Acid and Its Glucuronide Metabolites in Stable Adult Liver Transplant Recipients With Renal Dysfunction on a Low-Dose Calcineurin Inhibitor Regimen and Mycophenolate Mofetil

G. Gerken, V. Cicinnati, S. Beckebaum, 2009, Therapeutic drug monitoring.

Early Everolimus‐Facilitated Reduced Tacrolimus in Liver Transplantation: Results From the Randomized HEPHAISTOS Trial

H. Schlitt, P. Schemmer, B. Nashan, 2021, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Standardized Evaluation of Candidates Before Liver Transplantation With the Transplant Evaluation Rating Scale.

J. Scheel, A. Paul, Y. Erim, 2017, Psychosomatics.

Standardized Evaluation of Candidates Prior to Liver Transplantation with the Transplant Evaluation Rating Scale (TERS)Psychometric properties of the Transplant Evaluation Rating Scale

J. Scheel, A. Paul, C. Klein, 2016 .

Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial

V. Mazzaferro, P. Lamby, I. Bilbao, 2015, Transplantation.

Sorafenib treatment for recurrent hepatocellular carcinoma after liver transplantation.

A. Paul, S. Vernadakis, C. Klein, 2012, Transplantation proceedings.

Efficacy and safety of subcutaneous human HBV‐immunoglobulin (Zutectra®) in liver transplantation: an open, prospective, single‐arm phase III study

V. Cicinnati, S. Beckebaum, A. Pascher, 2011, Transplant international : official journal of the European Society for Organ Transplantation.

HCC recurrence in HCV‐infected patients after liver transplantation: SiLVER Study reveals benefits of sirolimus in combination with CNIs – a post‐hoc analysis

V. Mazzaferro, P. Lamby, I. Bilbao, 2020, Transplant international : official journal of the European Society for Organ Transplantation.

Predictive Factors of Outcome in Patients Transplanted for Hepatitis B

G. Gerken, V. Cicinnati, S. Beckebaum, 2009, Transplantation.

Compliance and tolerability of subcutaneous hepatitis B immunoglobulin self-administration in liver transplant patients: a prospective, observational, multicenter study.

V. Cicinnati, S. Beckebaum, S. Zeuzem, 2013, Annals of transplantation.

mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors.

V. Mazzaferro, I. Bilbao, U. Settmacher, 2020, Annals of surgery.

Efficacy, safety, and immunosuppressant adherence in stable liver transplant patients converted from a twice‐daily tacrolimus‐based regimen to once‐daily tacrolimus extended‐release formulation

G. Gerken, V. Cicinnati, S. Beckebaum, 2011, Transplant international : official journal of the European Society for Organ Transplantation.

Clinical trial: switch to combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patients – assessment of renal and allograft function, cardiovascular risk factors and immune monitoring

G. Gerken, V. Cicinnati, S. Beckebaum, 2007, Alimentary pharmacology & therapeutics.

Everolimus and Early Calcineurin Inhibitor Withdrawal: 3-Year Results From a Randomized Trial in Liver Transplantation

F. Lehner, N. Heyne, F. Rauchfuß, 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Long‐term follow‐up of five yr shows superior renal function with everolimus plus early calcineurin inhibitor withdrawal in the PROTECT randomized liver transplantation study

F. Lehner, N. Heyne, F. Rauchfuß, 2016, Clinical transplantation.

A Randomized, Controlled Study to Assess the Conversion From Calcineurin‐Inhibitors to Everolimus After Liver Transplantation—PROTECT

F. Lehner, J. Klempnauer, G. Kazemier, 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Posttraumatic Stress Disorder, Quality of Life, and the Subjective Experience in Liver Transplant Recipients

S. Beckebaum, Y. Erim, G. Paslakis, 2018, Progress in transplantation.

Ribavirin with either standard or pegylated interferon to treat recurrent hepatitis C after liver transplantation

G. Gerken, V. Cicinnati, S. Beckebaum, 2007, Alimentary pharmacology & therapeutics.

Feasibility and Acceptability of an Alcohol Addiction Therapy Integrated in a Transplant Center for Patients Awaiting Liver Transplantation.

S. Beckebaum, A. Mayr, A. Helander, 2016, Alcohol and alcoholism.

Tacrolimus as a Reasonable Alternative in a Patient with Steroid-Dependent and Thiopurine-Refractory Autoimmune Pancreatitis with IgG4-Associated Cholangitis

A. Kahraman, G. Gerken, A. Canbay, 2014, Zeitschrift für Gastroenterologie.

Assessment of Allograft Fibrosis by Transient Elastography and Noninvasive Biomarker Scoring Systems in Liver Transplant Patients

G. Gerken, V. Cicinnati, S. Beckebaum, 2010, Transplantation.

Frailty as a predictive factor for survival after liver transplantation, especially for patients with MELD≤15—a prospective study

S. Tagay, M. Teufel, A. Paul, 2021, Langenbeck's Archives of Surgery.